Sign Out
Use in Pregnancy & Lactation: A foreign epidemiological study of vitamin A in pregnant women suggested an increased frequency of birth defects dominated by cranial neural crest defects in newborns delivered by women administered 10,000 IU/day or higher amounts of vitamin A during 3 months prior to pregnancy and the first 3 months of pregnancy. When AMINOLEBAN EN powder is administered to pregnant women during the first 3 months of pregnancy or women who have an intention to become pregnant, special attention should be paid to dosage, adjusting as necessary to achieve a reduction to less than 5,000 IU/day of vitamin A.
Use in the Elderly: Dosage reduction or other appropriate measures should be considered when prescribing AMINOLEBAN EN powder to elderly patients because these patients often have reduced physiological function.
Use in Children: The safety of AMINOLEBAN EN powder in low birth weight infants, newborns, suckling infants, infants, and children has not been established. Clinical experience is insufficient.
